Effects of Therapeutic Doses of Celecoxib on Several Physiological Parameters of Cultured Human Osteoblasts
Metadata
Show full item recordAuthor
Costela Ruiz, Víctor Javier; Melguizo Rodríguez, Lucía Raquel; Illescas Montes, Rebeca; Ramos Torrecillas, Javier; Manzano Moreno, Francisco Javier; Ruiz Rodríguez, Concepción; Luna Bertos, María Elvira DeEditorial
Ivyspring International Publisher
Materia
Celecoxib Human osteoblasts Osteoblast differentiation Bone COX-2 selective NSAIDs
Date
2019-09-20Referencia bibliográfica
Costela-Ruiz, V. J., Melguizo-Rodríguez, L., Illescas-Montes, R., Ramos-Torrecillas, J., Manzano-Moreno, F. J., Ruiz, C., & De Luna-Bertos, E. (2019). Effects of Therapeutic Doses of Celecoxib on Several Physiological Parameters of Cultured Human Osteoblasts. Int J Med Sci, 16(11), 1466-1472.
Sponsorship
This study was supported by research group BIO277 (Junta de Andalucía) and Department of Nursing (University of Granada). The work outlined in this article has been supported by the Spanish Ministry of Education under FPU fellowship reference FPU15-05635 and FPU16-04141.Abstract
Non-steroidal anti-inflammatory drugs (NSAIDs), including cyclooxygenase-2 (COX-2)-selective
NSAIDs, are associated with adverse effects on bone tissue. These drugs are frequently the
treatment of choice but are the least studied with respect to their repercussion on bone. The
objective of this study was to determine the effects of celecoxib on cultured human osteoblasts.
Human osteoblasts obtained by primary culture from bone samples were treated with celecoxib at
doses of 0.75, 2, or 5μM for 24 h. The MTT technique was used to determine the effect on
proliferation; flow cytometry to establish the effect on cell cycle, cell viability, and antigenic profile;
and real-time polymerase chain reaction to measure the effect on gene expressions of the
differentiation markers RUNX2, alkaline phosphatase (ALP), osteocalcin (OSC), and osterix (OSX).
Therapeutic doses of celecoxib had no effect on osteoblast cell growth or antigen expression but
had a negative impact on the gene expression of RUNX2 and OSC, although there was no significant
change in the expression of ALP and OSX. Celecoxib at therapeutic doses has no apparent adverse
effects on cultured human osteoblasts and only inhibits the expression of some differentiation
markers. These characteristics may place this drug in a preferential position among NSAIDs used for
analgesic and anti-inflammatory therapy during bone tissue repair.